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Introduction: Mineral bone disor-
der (MBD) is a common condition in 
chronic kidney disease (CKD) patients 
and causes significant morbidity and 
mortality. Data involving prevalence 
of alterations in bone histological pat-
terns, impact of different treatments 
and its repercussion in outcomes, such 
as bone fractures, hospitalization, car-
diovascular disease and mortality, are 
scarce. Data bank registry can be a valu-
able tool to understand epidemiologi-
cal aspects of MBD CKD. The Brazilian 
Registry of Bone Biopsy (REBRABO) 
will be a national registry, coordi-
nating by the Brazilian Society of Ne-
phrology - Committee of MBD-CKD. 
Objective: To describe REBRABO´s de-
sign, elements of data and methodolo-
gy. Methods: Will be an online na-
tional observational and multicentric 
data registry divided in two phases 
(retrospective, 1st phase) and prospec-
tive (2nd phase), including information 
from bone tissue histomorphometric 
analysis and demographics, clinical 
and laboratorial data from CKD-MBD 
patients. Results: The REBRABO´s 
first phase will explore data on de-
mographics, clinical, laboratorial and 
bone histomorphometric analysis data 
from January/1986 to December/2013. 
The first results are expected in early 
2015. Conclusion: Studies in the field 
of CKD-MBD are needed, particularly 
those analyzing its prevalence, associa-
tions between demographic, clinical, 
histological parameters, and major out-
comes. The REBRABO will be a unique 
retrospective and prospective research 
platform including bone biopsy data in 
CKD-MBD patients.
AbstrAct
Keywords: bone diseases; electronic health 
records; renal insufficiency, chronic.
IntroductIon
Mineral and bone disorders (MBD) 
are frequent in patients with chronic 
kidney disease (CKD) and they incre-
ase morbidity and mortality in these 
patients.1 These disorders are known 
by the CKD-MBD acronym and en-
compass biochemical changes, vascu-
lar and soft tissue calcifications, and 
renal osteodystrophy (RO), which 
makes up the bone diseases in CKD 
patients.2
Knowledge on the pathophysiology, 
diagnosis and treatment of CKD-
MBD has increased substantially 
in recent decades.3-6 Despite the 
advent of new bone remodeling 
biochemical markers,7,8 bone biopsy 
is still considered the gold standard 
for RO diagnosis.2,9 In Brazil, few 
laboratories analyze bone tissue 
without prior decalcification, with 
bone remodeling quantification by 
histomorphometry. It is estimated 
that in the last 30 years, around 
5,000 patients with CKD-MBD were 
studied employing this technique. 
These biopsies were analyzed mainly 
at the University of São Paulo (USP) 
and Federal University of São Paulo 
(UNIFESP), providing a wealth of 
data that needs to be computerized, 
processed and made available to the 
scientific community.
There are few studies in the 
literature that assess the prevalence 
of different types of RO, as well 
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as the impact of treatment and its effects on 
outcomes such as fractures, hospitalization, 
cardiovascular disease and mortality. In our 
setting, one study assessed the types of RO 
in 2,340 patients with stage 5D CKD (93.1% 
in hemodialysis), from 1985 to 2001.10 The 
results of this study showed an increased 
prevalence of secondary hyperparathyroidism 
related to bone disease and reduced prevalence 
of aluminum-intoxication in the 90s compared 
to the 80s.
New guidelines for the diagnosis and 
treatment of CKD-MBD were introduced in 
recent years, changing previously established 
paradigms.11-13 The prevalence of different 
types of RO has been modified over the last 
decade, especially the increased prevalence 
of static bone disease.14-16 However, more 
studies are needed for understanding 
the pathophysiology of CKD-MBD, its 
complications and the impact of therapy, 
with the goal of contributing to quality of life 
improvement and reducing the high mortality 
rates of these patients.
Within this context it is necessary to create 
records that identify the different types of RO, 
risk factors, symptoms and complications 
associated with these disorders. The Brazilian 
Registry of Bone biopsies (REBRABO) will 
be a national, multicentric, observational 
database, coordinated by the Chronic Kidney 
Disease Mineral and Bone Disorder (CKD-
MBD) Committee of the Brazilian Society of 
Nephrology (SBN). This register will examine 
demographic, clinical, laboratorial and 
histomorphometric parameters from bone tissue 
of patients with CKD-MBD retrospectively and 
prospectively.
REBRABO’s primary mission will be to 
identify associations between variables men-
tioned and their relationships with clinical 
outcomes. This information will serve as a re-
search platform to expand the knowledge about 
CKD-MBD.
The main objectives of REBRABO are:
•	 Create a database with national multicentric 
information from CKD-MBD patients as 
to changes found in bone biopsies;
•	 Obtain data on the demographic, clinical 
and laboratorial characteristics of patients 
submitted to bone biopsy;
•	 Identify associations between CKD-MBD 
and clinical outcomes, including mortality, 
fractures, hospitalizations and quality of 
life;
•	 Propose new guidelines for CKD-MBD 
diagnosis and treatment, aiming at quality 
of life and survival improvements.
dAtAbAse And methods
REBRABO will be a database containing demo-
graphic, clinical and laboratorial data on CKD-
MBD patients submitted to bone biopsy, as well 
as the results of these biopsies.
Data will be added by electronic means only, 
online, via a website physically located in com-
puters at the private data center, contracted for 
this purpose (e.g., Locaweb). The database is pro-
grammed in “PHP” languages (Hypertext pre-
processor), “JavaScript”, “HTML” (Hypertext 
Markup Language) and “Css” (Cascading Style 
Sheets), and is managed by MySQL system. Such 
data inclusion is to be performed by licensed 
physicians only, previously registered in the SBN 
or REBRABO database or through user authen-
tication via individualized password.
Initially (retrospective phase), we analyzed 
data from patients submitted to bone biopsies 
between 1986 and 2013, which processing and 
reports were carried out by the Kidney Hospital 
Bone Histomorphometry Labs/Oswaldo 
Ramos Foundation, Federal University of São 
Paulo (UNIFESP), São Paulo, Brazil, and Bone 
Histomorphometry Laboratory of the Kidney 
Pathophysiology - LIM-16, School of Medicine, 
University of São Paulo, São Paulo, Brazil. In 
the prospective phase we included patients 
whose bone biopsies were indicated by their 
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physicians, or patients who participated in 
clinical trials approved by a medical ethics and 
research committee. There will be no REBRABO 
interference on the indication of bone biopsy, or 
treatment of any patient.
These data will be organized and scanned 
according to a standard electronic form (Table 1, 
Figure 1, Appendices 1, 2 and 3). When the bone 
tissue analysis report becomes available, it will 
be included in REBRABO through a standard 
electronic form (Figure 2 and Appendix 4). 
For data analysis, researchers may use filters 
to exclude records that do not meet the specific 
criteria of each research.
To increase the communication potential 
and facilitate scientific research, REBRABO will 
adopt the terminology recommended by the 
Kidney Disease Improving Global Outcomes 
(KDIGO) guidelines, through the TMV 
classification [Turnover Mineralization and 
Volume].2 Quantitative histomorphometric data, 
when available, will be grouped according to the 
structural parameters of formation, resorption and 
mineralization, which nomenclature follows the 
standards of the American Society for Bone and 
Mineral Research (ASBMR)17 (Tables 2 and 3).
REBRABO data will be validated before its 
analysis. This process will take place by the 
very program structure, which will control 
data inclusion, preventing incorrect data entry. 
We have to bear in mind that all records will 
be checked by two different observers with 
experience in clinical research.
Data analysis will be descriptive and plotted 
on a frequency table for categorical and analytical 
variables, continuous variables which will be 
represented as mean ± standard deviation or as 
median and interquartile ranges, as appropriate. 
Groups with normal distribution will be 
compared using the Student t-test or ANOVA; 
and the Mann-Whitney or Kruskal-Wallis tests 
for groups with non-parametric distribution. 
Categorical variables will be analyzed using the 
chi-square or Fisher test. Correlation analysis 
between continuous variables will be made 
by the Pearson (parametric data) or Spearman 
(nonparametric data) tests. Statistical analysis 
will be performed using the SPSS software version 
17.1. The p < 0.05 value will be considered 
statistically significant.
Data use anD sharing
Researchers outside the CKD-MBD SBN commit-
tee can access REBRABO data upon request to 
the aforementioned Committee, through a stan-
dardized form. Applicants must sign a document 
accepting the use of data, confidentiality and 
publications terms and destruction of data after 
use. No data from REBRABO will be provided 
without signing this term of acceptance and work 
plan approval, or before the main analyses and pu-
blications from the CKD-MBD SBN Committee.
tAble 1 reBraBO Data cOllectiOn instruments
Document Description
Demographic/Clinical Census
(Appendix 1) Form used to collect demographic characteristics and clinical information from each patient. We will collect 
data such as age, gender, ethnicity, CKD etiology, kidney disease duration, time in dialysis, dialysis mode, comorbidities, 
history of fractures, cardiovascular events, and others.
Laboratorial census
(Appendix 2) Form used to collect laboratorial information in the last 6 months related to the bone biopsy date, including 
the following tests: ion calcium and/or total; phosphorus; alkaline phosphatase - total or bone fraction, parathyroid 
hormone(PTH); 25(OH)-vitamin D; creatinine; urea; hemoglobin; hematocrit; platelets; leucocytes; albumin; ferritin; 
aluminum; and others.
Bone tissue data analysis
(Appendix 3) Form used to collect information on bone histology according to quantitative and semiquantitative 
histomorphometric parameters (Table 3 and Appendix 3).
CKD: Chronic kidney disease.
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Figure 1. Standard electronic form for data entry from the 
Demographic/Clinical Census.
Figure 2. Standard electronic form for data entry related to the reports 
from the bone tissue analysis.
tAble 2 tmV classificatiOn system
Parameters Classification
Turnover (R) low normal high
Mineralization (M) normal abnormal NA
Volume (V) reduced normal high
T: Turnover; M: Mineralization; V: Volume; NA: Not applicable.
PrOtectiOn Of research suBjects
The coordinator of the REBRABO will send 
data to the participating center preserving the 
patient’s identity. There will not be any form of 
influence on patient bone biopsy or treatment 
indications, emphasizing that this database is 
only observational. It’s up to each physician 
participating in REBRABO to obtain the consent 
of each patient, as well as signing and keeping 
tAble 3 structural Patterns Of BOne fOrmatiOn,  
 resOrPtiOn anD mineralizatiOn frOm the BOne  
 tissue histOmOrPhOmetric analyses
Structural parameters unit
Bone volume (BV/TV) %
Bone ridges thickness (Tb.Th) µm
Ridges separation (Tb.Sp) µm
Number of bone ridges (Tb.N/mm)/mm
Formation parameters
Osteoid volume (OV/BV) %
Osteoid thickness (O.Th) µm
Osteoid surface (OS/BS) %
Osteoblastic surface (Ob.S/BS) %
Resorption parameters
Resorption surface (ES/BS) %
Osteoclastic surface (Oc.S/BS) %
Mineralization parameters
Mineralizing surface (MS/BS) %
Mineral settling rate (MAR) µm/day
Bone formation rate (BFR/BS) µm3/µm2/day
Corrected bone formation rate (Aj.AR) µm/day
Mineralizing time interval (Mlt) day
Medullary fibrosis
Fibrosis volume (Fb.V) %
Metal deposits
Aluminum-covered surface (Al.S/BS) %
Iron-covered surface (Fe.S/BS) %
the patient’s signed informed consent (IC) form 
for data inclusion in REBRABO.
conclusIon
There is a paramount need for studies 
assessing the prevalence, associations between 
sociodemographic, clinical, laboratorial and 
bone-tissue histomorphometric variables and 
their relationships with clinical outcomes in the 
CKD-MBD field. REBRABO will be one of the 
largest databases of bone biopsies from patients 
with BMD, especially associated with CKD, 
and will serve as a research platform for future 
studies in this field.
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AppendIx 1 DemOgraPhic/clinical census fOrm
Name: _____________________________________________________________________
CPF (If child, use the CPF from one of the parents): _________________________________
Home phone #: __________ Cell phone #: ______________________________
City: __________ State: __________
Patient’s ID number at REBRABO: _____________
Origin center: Name of the biopsy center: _________________
Name of the professional in charge of adding the data:
Medical specialty that indicated the bone biopsy:
□ Nephrology □ Endocrinology □ Rheumatology □ Orthopedics
□ Other ___________
Age (complete years): ___
Weight: __,_ kg Height: _,__ m
Residual clearance: __,_ ml/min
Gender:
□ Male □ Female
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Ethnicity:
□ White □ Black □ Brown □ Yellow
□ Indigenous □ Other __________
Bone biopsy indication:
□ Atraumatic fracture □ Persisting bone pain
□ Hyperphosphatemia 
and/or unexplained 
hypercalcemia
□ Possible aluminum 
intoxication
□ Pre-parathyroidectomy □ Pre osteoporosis therapy □ Clinical study □ Other
Bone biopsy date: ____________(dd/mm/yyyy)
CKD etiology:
□ Hypertension □ diabetes mellitus □ Chronic glomerulonephritis □ Chronic pyelonephritis
□ Polycystic kidney disease □ Kidney stones □ Congenital nephropathy □ Hereditary nephropathy
□ Undetermined □ Other: _________ □ None
Time of kidney disease (months): ___ □ Unknown
Time in dialysis (months): ___ □ Unknown
Dialysis mode:
□ Hemodialysis □ Peritoneal dialysis - CAPD □ Peritoneal dialysis - APD
Current kidney transplant:
□ No □ Yes, duration (0 to 360 months): ______
Previous kidney transplant:
□ No □ Yes, duration (0 to 360 months): _______ □ Unknown
Comorbidities:
□ Hypertension □ diabetes mellitus □ Dyslipidemia □ Coronary disease
□ Smoking □ Obesity □ Malnutrition 
□ Chronic inflammatory 
disease
□ Menopause
□ Peripheral arterial 
hypertension
□ Hepatitis C
□ Mineral bone disorder 
complication in CKD
□ Neoplasia □ None □ Other: _________
Bone pain intensity reported by the patient (visual analogue):
□ 0: no pain □ 1 □ 2 □ 3
□ 4 □ 5: maximum pain
Other signs and symptoms:
Weakness: □ No □ Yes
Tendon rupture: □ No □ Yes
Deformities: □ No □ Yes
Pruritus: □ No □ Yes
Red eye: □ No □ Yes
Myalgia: □ No □ Yes
Skin lesion: □ No □ Yes
Fracture: □ No □ Yes
Personal medical history:
□ Parathyroidectomy (dd/mm/yyyy) Type: ____
□ Bone biopsy (dd/mm/yyyy)
□ Atraumatic bone fracture □ Aluminum intoxication
□ Acute myocardial 
infarction
□ Cerebral vascular accident
□ None □ Other: ___
contInued AppendIx 1.
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Medications in current use:
□ Calcium carbonate □ Calcium acetate □ Sevelamer hydrochloride □ Sevelamer carbonate
□ Calcitriol PO □ Calcitriol IV □ Paricalcitol □ D3 or D2 Vitamin
□ Cinacalcet □ Bisphosphonate □ Corticosteroids □ Dicumarinic
□ Carbamazepine □ Deferoxamine □ None □ Other
contInued AppendIx 1.
AppendIx 2 laBOratOrial census fOrm laBOratOrial census fOrm
Fill out the results from the blood workup, using the bone biopsy date as a reference (inform the result closest to the 
bone biopsy date)
Ion calcium: _____________ unit: __/__
Total calcium: ______________ (mg/dl):
Phosphorus: _________________ (mg/dl):
Parathyroid hormone (PTH): ________ (pg/ml)
Total alkaline phosphatase: ________________ (UI/l):
Alkaline phosphatase bone fraction: _____________ (UI/I or %)
Albumin: ___________________ (g/dl):
25(OH)-vitamin D: ____________________ (ng/ml)
Creatinine:_________________________ (mg/dl)
Urea: ______________________ (mg/dl)
Hemoglobin: ___________________ (g/dl)
Hematocrit: ____________________ (%)
Ferritin: _______________________ (mg/dl)
C-Reactive Protein: _______________________ (mg/dl)
Bicarbonate: ___________________________ (mmol/l)
Aluminum: _______________________ (µg/L)
B2 microglobulin: ________________________ (ng/ml)
AppendIx 3 image exams census fOrm
Radiographies: (Classify the type of disorder as localized or diffuse)
Radiographies □ No □ Yes
Vascular calcification □ No □ Yes, Type: __________
Fracture signs □ No □ Yes
Signs of resorption □ No □ Yes, Type: ___________
Osteopenia □ No □ Yes, Type: ___________
Signs of brown tumor □ No □ Yes
Bone deformities □ No □ Yes
Bone densitometry:
Osteoporosis:
□ No □ Yes
Osteopenia:
□ No □ Yes
Parathyroid scintigraphy:
Signs of hyperparathyroidism:
□ No □ Yes
Positive uptake in:
□ Right upper pole □ Left upper pole □ Right lower pole □ Left lower pole
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Parathyroid ultrasound scan:
Signs of hyperparathyroidism:
□ No □ Yes
Number of glands found: __
contInued AppendIx 3.
AppendIx 4 BOne tissue analysis Data
□ Fragment inadequate for the diagnosis
Structural parameters:
Bone volume (BV/TV): __,_%
Bone trabeculae thickness 
(Tb.Th): __,_µm
Bone trabeculae separation 
(Tb.Sp): __,_µm
Number of bone trabeculae 
(Tb.N/mm): __,_/mm
Forming parameters
Osteoid volume (OV/BV): __,_%
Osteoid thickness (O.Th): __,_µm
Osteoid surface (OS/BS): __,_%
Osteoblastic surface (Ob.S/BS): __,_%
Resorption parameters
Resorption surface (ES/BS): __,_%
Osteoclastic surface (Oc.S/BS): __,_%
Mineralization parameters
Mineralizing surface (MS/BS): __,_%
Mineral deposition rate (MAR): __,_µm/day
Bone formation rate (BFR/BS): __,_µ3/µ2m/day
Corrected bone formation rate (Aj.AR): __,_µm/day
Mineralization time interval (Mlt): __,_days
Fibrosis:
Fibrosis volume (Fb.V): __,_%
Metal deposits:
Aluminum-coated surface (Al.S/BS): __,_%
Iron-coated surface (Fe.S/BS): __,_%
Report (semiquantitative analysis): __________________________________________________________________________
_________________________________________________________________________________________________________
_________________________________________________________________________________________________________
_________________________________________________________________________________________________________
Remodeling, mineralization and volume (RMV):
Remodeling: □ High (+1) □ Medium (0) □ Low (-1)
Mineralization: □ Normal (0) □ Abnormal (99)
Volume: □ High (+1) □ Normal (0) □ Reduced (-1)
Aluminum intoxication: □ No □ Yes (if > 30%)
Iron intoxication: □ No □ Yes
